TTOO with a beautiful coil primed to jump I like the pattern. Nice little coil waiting to pop. If it breaks bullish you have an easy RR setup with targets of 3.30 and 4.50. After that just move with the averages. Enjoy! Longby rolerkoester1223
TTOO - Federal Contract Creating Hype. Above The TrendT2 Biosystems, Inc. engages in the development of proprietary technology platform. It offers the T2 Magnetic Resonance technology which enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types. It products include T2Bacteria Panel, T2Candida Panel, T2Dx Instrument, AND T2MR Technology. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA. SHORT INTEREST 5.5M 08/30/19 P/E Current -2.07 P/E Ratio (with extraordinary items) -2.04 Average Recommendation: OVERWEIGHT Average Target Price: 3.71Longby DEXWireNews15
Bad chat still, but a revolutionary product $TTOO chart is still nothing to talk about. However please keep in mind my target is at least $25 a share (not a typo). If interested, please read my latest article in SA to understand why seekingalpha.comLongby market-talk222
Catalyst investing with T2 Biosystems (TTOO)Shares of T2 Biosystems (TTOO) have fallen by roughly 75% since the company's IPO was priced at $11 in 2014. Over the past 3 years, the share price has lost roughly two-thirds of its value and so far 2019 has seen further decline. Technical argument Limited: it’s no easy task trying to evaluate identify trading opportunities in price trends and patterns seen in small market capitalisation biotechnology. TTOO stock price is volatile because it is in possession of a breakthrough technology with its success relying on pivotal data that has not yet been made public. In addition, concerns remain, including cash burn and near-term financing. Even if TTOO is successful in achieving approval for various products the company may have difficulty getting hospitals and labs to adopt the technology. I have included indictors such as MACD, momentum, Moving Average MA, Relative Strength Index RSI and Point of Control POC. The conclusions from these indicators are limited, I have explained each individually on the graph. What I do draw from the graph is that TTOO has fallen back into the Point of Control: price point with the highest trade volume. We can see a bullish RSI divergence: TTOO makes a lower low and RSI forms a higher low and volume has started to increase. If investors consider the stock to be oversold the volume with continue to increase as traders buy stock and we will see a price rise. I would NOT buy stock based on this analysis because the volume spike could be investors offloading stock, even if we are at an all-time low. So let’s ignore the technical analysis because in this situation making an investment decision based solely on evaluating price trends won’t have any bearing on the outcome of upcoming catalysts and therefore the stocks potential value. Upcoming catalysts The company is in possession of a breakthrough technology for the detection of sepsis. A possible near-term catalyst for upside is results of the T2Bacteria Panel pivotal FDA clinical trial to be published in a peer-reviewed medical journal in Q2 2019 T2Lyme Panel is currently in a pivotal Phase 3 trial with very encouraging results so far and a $700 million market being targeted. Longby warrenhochfeld0
TTOO H&S Pattern completedNote: This is not an investment advice but my opinion alone. Please feel free to comment. TTOO just completed the H&S and looks to be setting a bullish RSI even with the current sell off. Looks to me that buyers are stepping in to buy shares.Longby UnknownUnicorn32726721
T2 breaking away from the 20 dayexpanding from the 20 day on accum vol. Still holding and added more. Longby billgarc1
Swinging TTOOBeauty candle Tues, higher low yesterday, long today @ $6.13. Expecting a little more over next few sessionsLongby billgarc1